Moderna Inc said that its candidate vaccine, mRNA-1273, was 94.5% effective in preventing Covid-19 disease in a large Phase 3 study that enrolled more than 30,000 participates in the US. The compound is a messenger RNA (mRNA) vaccine against Covid-19 encoding for a prefusion stabilised form of the SARS-CoV-2 spike protein. It was co-developed by Moderna and the US National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.
